Evocalcet manufacturers
- Evocalcet
-
-
2026-07-27
- CAS:870964-67-3
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1000kg
- Evocalcet
-
- $31.00
-
2026-07-09
- CAS:870964-67-3
- Purity: 98.88%
- Supply Ability: 10g
- Evocalcet
-
-
2026-06-30
- CAS:870964-67-3
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 10000KGS
Related articles - A cinacalcet analog-Evocalcet
- Evocalcet, a novel oral calcimimetic agent, is an allosteric modulator that acts on the calcium-sensing receptors on the membr....
- Dec 26，2023
|
| | Evocalcet Basic information |
| Product Name: | Evocalcet | | Synonyms: | Evocalcet;Benzeneacetic acid, 4-[(3S)-3-[[(1R)-1-(1-naphthalenyl)ethyl]amino]-1-pyrrolidinyl]-;2-{4-[(3S)-3-{[(1R)-1-(Naphthalen-1-yl)ethyl]amino}pyrrolidin-1-yl]phenyl}acetic acid;Calcium-sensing receptor,KHK-7580,Inhibitor,KHK 7580,CaSR,Evocalcet,inhibit;Ivocase;MT 4580;MT4580;MT-4580 | | CAS: | 870964-67-3 | | MF: | C24H26N2O2 | | MW: | 374.48 | | EINECS: | | | Product Categories: | | | Mol File: | 870964-67-3.mol |  |
| | Evocalcet Chemical Properties |
| Boiling point | 594.4±50.0 °C(Predicted) | | density | 1.23±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF:5.0(Max Conc. mg/mL);13.35(Max Conc. mM)
DMSO:5.0(Max Conc. mg/mL);13.35(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:2):0.3(Max Conc. mg/mL);0.81(Max Conc. mM) | | form | A crystalline solid | | pka | 4.71±0.10(Predicted) | | color | White to off-white | | InChI | InChI=1S/C24H26N2O2/c1-17(22-8-4-6-19-5-2-3-7-23(19)22)25-20-13-14-26(16-20)21-11-9-18(10-12-21)15-24(27)28/h2-12,17,20,25H,13-16H2,1H3,(H,27,28)/t17-,20+/m1/s1 | | InChIKey | RZNUIYPHQFXBAN-XLIONFOSSA-N | | SMILES | C1(CC(O)=O)=CC=C(N2CC[C@H](N[C@@H](C3=C4C(C=CC=C4)=CC=C3)C)C2)C=C1 |
| | Evocalcet Usage And Synthesis |
| Uses | 4-[(3S)-3-[[(1R)-1-(1-Naphthalenyl)ethyl]amino]-1-pyrrolidinyl]benzeneacetic Acid is part of a pharmaceutical composition that is a therapeutic agent for hyperparathyroidism. | | in vivo | Evocalcet (0.03 or 0.3 mg/kg; oral Administration, once) affects serum PTH and Ca levels[1].
Evocalcet (0.3 mg/kg; oral Administration, once daily, for 5 weeks) reduces the serum PTH and Ca levels and increases the serum IP (inorganic phosphorus) level[1]. | Animal Model: | Male Sprague Dawley chronic kidney disease (CKD) rats with adenine induced secondary hyperparathyroidism (SHPT)[1] | | Dosage: | 0.03 and 0.3 mg/kg | | Administration: | Oral Administration; 0.03 and 0.3 mg/kg, once | | Result: | Decreased the serum PTH and Ca levels at a dose of 0.3 mg/kg.
|
|
| | Evocalcet Preparation Products And Raw materials |
|